Date post: | 21-Apr-2017 |
Category: |
Education |
Upload: | manahrsinh-rajput |
View: | 15 times |
Download: | 0 times |
Recent advances in the management of Testicular tumor
1
RECENT ADVANCES IN THE MANAGEMENT OF TESTICULAR TUMOR
PRESENTER: Dr.Manharsinh Rajput
December 16
Recent advances in the management of Testicular tumor
2
Testicular Descent
December 16
Recent advances in the management of Testicular tumor
3
ANATOMY
December 16
Fig 5. Anatomy of the testis
Recent advances in the management of Testicular tumor
4
BLOOD SUPPLY
December 16
Fig 6. Blood supply of testis
Recent advances in the management of Testicular tumor
5
LYMPHATIC DRAINAGE
December 16
Fig. 7 Lymphatic drainage
Recent advances in the management of Testicular tumor
6
INTRODUCTION
• Testicular cancer accounts for only about 1% of all human neoplasms.
• Testicular cancer although rare, is the most common malignancy in men in 15-35 years age group and accounts for approximately 23% of all cancers in this group.
• Risk factors
December 16
Recent advances in the management of Testicular tumor
7
WHO CLASSIFICATIONGerm cell tumors:Precursor lesions- Intratubular malignant germ cell tumor (carcinoma in situ)Tumors of one histologic type (pure forms) Seminoma variant- seminoma with syncitiotrophoblastic cells Spermatocytic seminoma variant- spermatocytic seminoma with sarcoma Embryonal carcinoma Yolk sac tumor Polyembryoma
Trophoblastic tumors- choriocarcinoma
Teratoma Mature teratoma Dermoid cyst Immature teratoma Teratoma with malignant areasMixed tumors
December 16
Recent advances in the management of Testicular tumor
8
CLASSIFICATION CONT..Sex cord/ Gonadal Stromal Tumors:Pure forms Leydig’s cell tumor Sertoli’s cell tumor large cell calcifying lipid rich cellGranulosa cell tumor Adult type granulosa cell tumor Juvenile type granulosa cell tumorTumors of thecoma / fibroma group
Incompletely differentiated sex cord/ gonadal stromal tumors
Mixed forms
Unclassified forms
Tumors containing both germ cell and sex cord/gonadal stromal elements -Gonadoblastoma -Mixed germ cell- sex cord/ gonadal stromal tumors, unclassifiedMiscellaneous tumors -Carcinoid tumors -Tumors of ovarian epithelial types
December 16
Recent advances in the management of Testicular tumor
9
CLASSIFICATION CONT..Lymphoid and hematopoietic tumors: -Lymphoma - Plasmacytoma - LeukemiaTumors of collecting duct and rete: -Adenoma -CarcinomaTumors of tunica, epididymis, spermatic cord, supporting structures, and appendices: Adenomatoid tumor Mesothelioma Adenoma Carcinoma Melanotic neuroectodermal tumor. Soft tissue tumors
Unclassified tumors
Secondary tumors
December 16
Recent advances in the management of Testicular tumor
10
SEMINOMA
Age of presentation 3rd and 4th decade Presentation present with uniform testicular swelling Serum markers are rarely elevated. AFP never rises. Lymphatic spread Good prognosis
NON SEMINOMA
2nd and 3rd decade
present with multinodular testicular swelling.
Serum markers are commonly elevated.
Lymphatic as well as hematogenous.
Worse prognosis
December 16
Recent advances in the management of Testicular tumor
11
CLINICAL FEATURES
Painless Swelling of Testes
Dull Ache or Heaviness in Lower Abdomen
10% - Acute Scrotal Pain
10% - Present with Metatstasis• - Neck Mass / Cough / Anorexia / Vomiting / Back Ache/ Lower limb swelling
5% - Gynecomastia
Rarely - Infertility
December 16
Recent advances in the management of Testicular tumor
12
• Physical Examination
• Careful examination of the affected and the normal contralateral testis
• Examine for any evidence of palpable abdominal mass, inguinal
lymphadenopathy, supraclavicular lymphadenopathy.
• Chest examination for intrathoracic disease.
December 16
Recent advances in the management of Testicular tumor
13
INVESTIGATIONS
1. Scrotal Ultrasound 2. CT Thorax / Chest X-Ray - PA and lateral views3. CT Scan Abdomen & Pelvis4. Tumour Markers
- AFP- HCG- LDH- PLAP
5. MRI/PET Scan
December 16
Recent advances in the management of Testicular tumor
14
ROLE OF FNAC & BIOPSY
• In patients with an atrophic testis, history of cryptorchidism, or age
younger than 40 years, the prevalence of ITGCN in the contralateral testis
has been reported to be 36%.
December 16
Recent advances in the management of Testicular tumor
15
CLINICAL STAGINGStage I - Tumour confined to testis.
Stage II - Spread to Regional nodes.
Stage III - Spread beyond retroperitoneal Nodes or Above Diaphragm or visceral disease
December 16
Recent advances in the management of Testicular tumor
16
TNM STAGINGT0 = No evidence of TumourT1s = Intratubular, pre invasiveT1 = Confined to TestisT2 = Invades beyond Tunica Albuginea or into EpididymisT3 = Invades Spermatic CordT4 = Invades Scrotum
N1 = Single < 2 cmN2 = Multiple < 5 cm / Single 2-5 cmN3 = Any node > 5 cm
Mo = No distant metastasisM1 = Distant metastasis(M1a = Nonregional or pulmonary , M1b = sites other than m1a)
December 16
Recent advances in the management of Testicular tumor
17December 16
Recent advances in the management of Testicular tumor
18
TREATMENT
After obtaining serum AFP & B-HCG levels in suspected case of malignant germ cell tumor.
Radical inguinal orchiectomy with high ligation of spermatic cord is done, it is both diagnostic & therapeutic.
Further management depends on, pathology & stage of disease.
December 16
Recent advances in the management of Testicular tumor
19
SEMINOMA
Stage I,IIA Stage IIB,IIC,III
Retroperitoneal irradiation
BEP / EP
1.Non responder or discrete residual mass>3 cm– Excision2.35% residual mass harbours active disease—salvage chemotherapy
Responder
December 16
Recent advances in the management of Testicular tumor
20
NSGCT
Stage I,IIA Stage IIB,IIC,III
RPLND BEP / EP
1.Partial response RPLND/Excision of lung nodule2.Residual disease with raised tumor marker Salvage chemotherapy
Complete ResponseSurveillance
Follow up
December 16
Recent advances in the management of Testicular tumor
21
SURGERY
• Radical orchiectomy• Diagnostic and Therapeutic treatment of choice.• Complete removal of ipsilateral epididymis and spermatic cord to the level
of the internal inguinal ring.
• Partial orchiectomy• Considered in patient with polar tumor measuring 2 cm or less & abnormal
or absent c/l testis.• Adjuvant radiotherapy is given postoperatively.
• Delayed orchiectomy• Advanced NSGCT based on biopsy of metastatic site without primary
orchiectomy.
December 16
Recent advances in the management of Testicular tumor
22
RETROPERITONEAL LYMPH NODE DISSECTION
• The rationale for primary RPLND is that, in contrast to most
malignancies, testicular GCT is surgically curable in most patients with
low volume regional metastases.
• The rationale for performing PC-RPLND.
• Salvage PC-RPLND
• Desperation PC-RPLND
• Reoperative RPLND
December 16
Recent advances in the management of Testicular tumor
23
Fig. 8 Laparoscopic RPLND Port Placement
December 16
Recent advances in the management of Testicular tumor
24
Fig. 9 Robotic assisted RPLND Port Placement
December 16
Recent advances in the management of Testicular tumor
25
RADIATION THERAPY• Indications
– Adjuvant therapy for stages I–II b diseases– Salvage of loco-regional failure after surgery or chemotherapy– Palliative treatment to loco-regional or distant metastatic sites
• Techniques– EBRT to lymph nodes– High-energy radiation (6 – 18 MV)
• Seminoma is extremely radiosensitive. Radiation therapy is often used for adjuvant therapy for early-stage seminoma, and its use in non-seminoma germ cell tumors (GCT) is limited.
December 16
Recent advances in the management of Testicular tumor
26
• Fig. 10 Paraaortic and ipsilateral inguinal field for stage II left testicular seminoms, with inclusion of the renal hilus.
December 16
Recent advances in the management of Testicular tumor
27
Radiation cont..STAGE DOSE
I 20 Gy in 10# to para-aortic ± pelivic lymph node by ap-pa field
II 25Gy in 20 # by AP-PA
III 25 Gy in 20 # F/B 10 Gy in 5 #
December 16
Recent advances in the management of Testicular tumor
28
CHEMOTHERAPY• Indications
– As an alternative to adjuvant RT for stages I–II seminoma– Adjuvant therapy for stages II–IV seminoma
• Regimens – Single-agent carboplatin become an alternative for stage I seminoma– Regimens including BEP, EP, PVB, and VIP for stages II–IV diseases
Drug/ combination Dose and scheduleBleomycin 30 IU IV bolus on days 2,9,16Etoposide 100 mg/m2 IV over 30 mins on
days 1-5
Cisplatin 20 mg/m2 IV over 15-30 mins on days 1-5
Repeat cycle every 21 days for 3 or 4 cycles
December 16
Recent advances in the management of Testicular tumor
29
Chemotherapy cont..EP
Etoposide 100 mg/m2 IV over 30 mins on days 1-5
Cisplatin 20 mg/m2 IV over 15-30 mins on days 1-5
Repeat cycle every 21 days for 4 cycles
VeIPVinblastine 0.11 mg/kg/d on days 1 and 2
Ifosfamide 1.2 g/m2/d IV on days 1-5
Cisplatin 20 mg/m2/d IV on days 1-5
Mesna 400 mg/m2/d IV bolus prior to ifosfamide dose, then 1.2 g/m2/d IV infused continuously for 5 days
Repeat cycle every 21 days for 4 cycles
December 16
Recent advances in the management of Testicular tumor
30
CONCLUSION
Most common curable malignancy of young adults.
Most common- germ cell tumors, Seminoma > nonseminoma
Nonseminoma occurs a decade earlier.
Surgery is the main modality of treartment followed by Radiotherapy & or
chemotherapy for seminoma and chemotherapy & RPLND for
nonseminoma.• New tumor markers –HMGA1/2, OCT ¾, SOX2
December 16